EVM18 / Everest Medicines - LARVOL DELTA

Post-Reporting Period achievements and expected milestones (Everest Medicines Press Release) - "We plan to pursue global IND filing for EVM18 in the second half of 2026."

IND • Immunology • Oncology

Everest Medicines Announces Interim Results for First Half of 2025 (PRNewswire) - "EVM18, the in vivo CAR-T program, has completed multiple non-human primates (NHPs) trials and achieved preclinical proof-of-concept, with first-in-human data expected to initiate by the end of 2025....We expect to enroll first patient in the EVM14 program in the U.S. in the second half of 2025. We expect to receive IND approval on EVM14 from China's NMPA in the second half of 2025. We expect to achieve preclinical candidate milestone in the mRNA in vivo CAR-T program in the second half of 2025. We expect to complete patient enrollment of EVM16 IIT study in the second half of 2025."

New trial • Trial status • Oncology • Solid Tumor